Live Analyst Rating Changes 19064 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Yigal Nochomovitz
Citi

Yigal Nochomovitz

Citi
Wall Street Analyst
★★☆☆☆
#2463
on 13Foresight · ranked by our own returns
48%
Success Rate
+4.7%
Average Return
39 of 81 calls profitable · -1.6% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 48% of Yigal Nochomovitz's ratings turned a profit when each position was held for 1 year — averaging +4.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

207 Buy 12 Hold 11 Sell
Yigal's Stock Coverage 64 ratings · 2026-08-06
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ONC
BeOne Medicines
 Aug 06, 2026 BUY Strong Buy
+8.8% avg upside
28 analysts
$466.00
42.29% Upside
 · ·
SNDX
Syndax Pharmaceuticals
 Aug 05, 2026 BUY Strong Buy
+79.9% avg upside
27 analysts
$57.00
186.18% Upside
 -1.3% ·
RARE
Ultragenyx Pharmaceutical
 Aug 05, 2026 BUY Strong Buy
+162.3% avg upside
36 analysts
$45.00
80.43% Upside
 · ·
EYPT
EyePoint Pharmaceuticals
 Aug 05, 2026 BUY Strong Buy
+177.3% avg upside
20 analysts
$35.00
185.67% Upside
 · ·
TVTX
Travere Therapeutics
 Aug 05, 2026 BUY Strong Buy
-16.6% avg upside
22 analysts
$85.00
35.42% Upside
 +1.9% ·
RIGL
Rigel
 Aug 05, 2026 BUY Strong Buy
-40.0% avg upside
17 analysts
$83.00
104.95% Upside
 +0.0% ·
KRYS
Krystal Biotech
 Aug 04, 2026 BUY Strong Buy
-20.5% avg upside
19 analysts
$386.00
18.53% Upside
 +0.3% ·
CRSP
Crispr Therapeutics AG
 Aug 03, 2026 BUY Buy
+45.0% avg upside
41 analysts
$88.00
67.73% Upside
 +5.8% ·
SPTX
Seaport Therapeutics, Inc.
 Aug 03, 2026 BUY Strong Buy
+71.9% avg upside
6 analysts
$35.00
56.57% Upside
 · ·
NBIX
Neurocrine
 Aug 03, 2026 BUY Strong Buy
+15.2% avg upside
37 analysts
$249.00
54.23% Upside
 -3.9% ·
SMMT
Summit Therapeutics
 Jul 24, 2026 BUY Strong Buy
+111.8% avg upside
27 analysts
$40.00
195.67% Upside
 -0.9% ·
RCUS
Arcus Biosciences
 Jul 22, 2026 BUY Strong Buy
+23.9% avg upside
20 analysts
$45.00
62.46% Upside
 -5.0% ·
LGND
Ligand Pharma
 Jul 21, 2026 BUY Strong Buy
-11.6% avg upside
15 analysts
$387.00
27.83% Upside
 -0.9% ·
SRPT
Sarepta Therapeutics
 Jul 20, 2026 SELL Buy
+271.2% avg upside
49 analysts
$13.00
18.36% Downside
 +11.7% ·
CADL
Candel Therapeutics
 Jun 30, 2026 BUY Strong Buy
+73.4% avg upside
11 analysts
$26.00
148.61% Upside
 +2.0% ·
ZYME
Zymeworks
 Jun 30, 2026 BUY Strong Buy
+37.4% avg upside
25 analysts
$37.00
57.47% Upside
 -16.0% ·
ACAD
ACADIA Pharmaceuticals
 Jun 26, 2026 BUY Strong Buy
+27.4% avg upside
43 analysts
$35.00
21.47% Upside
 +7.2% ·
MIRM
Mirum Pharmaceuticals
 Jun 14, 2026 BUY Strong Buy
+10.7% avg upside
22 analysts
$145.00
37.03% Upside
 -5.7% ·
BMEA
Biomea Fusion
 Jun 11, 2026 BUY Strong Buy
+966.1% avg upside
15 analysts
$7.00
455.49% Upside
 +2.5% ·
CRBU
Caribou Biosciences
 Jun 11, 2026 BUY Strong Buy
+593.7% avg upside
12 analysts
$8.00
396.90% Upside
 -5.4% ·
STTK
Shattuck Labs
 Jun 09, 2026 BUY Strong Buy
+195.3% avg upside
15 analysts
$18.00
144.20% Upside
 +67.7% ·
SLDB
Solid Biosciences
 Jun 04, 2026 BUY Strong Buy
+82.0% avg upside
23 analysts
$14.00
60.37% Upside
 +12.4% ·
AVBP
ArriVent BioPharma, Inc.
 Jun 03, 2026 BUY Strong Buy
+38.5% avg upside
15 analysts
$43.00
40.44% Upside
 +2.8% ·
OLMA
Olema Pharmaceuticals
 May 31, 2026 BUY Strong Buy
+231.2% avg upside
16 analysts
$62.00
435.44% Upside
 -11.2% ·
KRRO
Korro Bio
 May 18, 2026 BUY Strong Buy
+137.3% avg upside
19 analysts
$21.00
82.55% Upside
 +15.3% ·
ZBIO
Zenas BioPharma, Inc.
 May 13, 2026 BUY Strong Buy
+34.0% avg upside
11 analysts
$41.00
28.64% Upside
 +57.8% ·
LENZ
LENZ Therapeutics
 May 13, 2026 BUY Buy
+348.1% avg upside
17 analysts
$20.00
279.51% Upside
 -34.2% ·
LXRX
Lexicon Pharmaceuticals
 May 11, 2026 BUY Buy
+63.0% avg upside
9 analysts
$3.10
26.50% Upside
 · ·
ZLAB
Zai Lab
 May 08, 2026 BUY Strong Buy
+220.7% avg upside
13 analysts
$44.00
139.61% Upside
 -2.5% ·
ORIC
Oric Pharmaceuticals
 May 05, 2026 BUY Strong Buy
+82.5% avg upside
19 analysts
$16.00
23.75% Upside
 +40.8% ·
ARVN
Arvinas Holding Company
 May 01, 2026 BUY Buy
+237.5% avg upside
28 analysts
$24.00
185.68% Upside
 -20.1% ·
IDYA
IDEAYA Biosciences
 Apr 13, 2026 BUY Strong Buy
+34.8% avg upside
29 analysts
$65.00
80.45% Upside
 +10.4% ·
DRTS
Alpha Tau Medical Ltd
 Mar 10, 2026 BUY Strong Buy
+4.9% avg upside
5 analysts
$9.00
32.11% Downside
 +93.9% ·
SGP
SpyGlass Pharma
 Mar 09, 2026 BUY Strong Buy
+89.8% avg upside
5 analysts
$42.00
77.28% Upside
 -12.7% ·
ARCT
Arcturus Therapeutics
 Mar 04, 2026 HOLD Buy
+373.2% avg upside
36 analysts
$8.00
27.86% Upside
 -17.4% ·
ARDX
Ardelyx
 Jan 08, 2026 BUY Strong Buy
+183.4% avg upside
21 analysts
$14.00
185.13% Upside
 -29.3% ·
PROK
ProKidney
 Sep 03, 2025 BUY Buy
+304.4% avg upside
12 analysts
$10.00
498.80% Upside
 -29.2% ·
PRQR
ProQR
 Mar 07, 2025 BUY Strong Buy
+482.7% avg upside
18 analysts
$4.00
103.09% Upside
 -6.8% ·
CLLS
Cellectis SA
 Dec 11, 2024 BUY Strong Buy
+619.5% avg upside
16 analysts
$11.00
294.36% Upside
 +174.7% ·
CHRS
Coherus Biosciences
 Dec 04, 2024 BUY Buy
+763.0% avg upside
18 analysts
$8.00
451.79% Upside
 -28.1% ·
CYVNY
Ceryvyn Therapeutics Limited
 Sep 12, 2024 BUY Hold
+33770.3% avg upside
7 analysts
$10.00
45354.48% Upside
 · ·
MGNX
MacroGenics
 Aug 15, 2024 BUY Buy
+350.8% avg upside
25 analysts
$14.00
259.00% Upside
 -51.5% ·
OVID
Ovid Therapeutics
 Jun 17, 2024 HOLD Strong Buy
+94.0% avg upside
18 analysts
$1.20
54.12% Downside
 -61.8% ·
FATE
Fate Therapeutics
 May 15, 2024 BUY Buy
+362.9% avg upside
31 analysts
$10.00
284.66% Upside
 -76.2% ·
ALDX
Aldeyra Therapeutics
 Dec 04, 2023 BUY Strong Buy
+904.8% avg upside
21 analysts
$8.00
399.98% Upside
 +51.7% ·
ATRA
Atara Biotherapeutics
 Nov 22, 2023 SELL Buy
+110.6% avg upside
18 analysts
$10.00
17.12% Upside
 +19.8% ·
IPHA
Innate Pharma
 Sep 18, 2023 BUY Strong Buy
+274.2% avg upside
10 analysts
$8.00
351.88% Upside
 -18.2% ·
OBX
Obsidian Therapeutics
 Aug 29, 2023 HOLD Buy
8 analysts
$0.25
 · ·
PTCT
PTC Therapeutics
 May 24, 2023 BUY Strong Buy
+17.0% avg upside
29 analysts
$63.00
8.96% Downside
 -20.8% ·
NCNA
Nucana
 Nov 28, 2022 BUY Buy
+840.3% avg upside
9 analysts
$2.00
49.15% Upside
 · ·
FR:IPH
Innate Pharma SA
 Sep 16, 2022 BUY Buy
+472.8% avg upside
5 analysts
$12.00
675.11% Upside
 +7.6% ·
ELVN
Enliven Therapeutics
 Apr 05, 2022 HOLD Strong Buy
-8.8% avg upside
14 analysts
$8.00
86.54% Downside
 +353.9% ·
PBYI
Puma Biotechnology
 Sep 27, 2021 BUY Buy
+427.6% avg upside
11 analysts
$11.00
37.66% Upside
 -68.1% ·
SYBX
Synlogic
 Aug 21, 2019 SELL Buy
+1940.9% avg upside
11 analysts
$2.00
69.53% Upside
 · ·
AKBA
Akebia Therapeutics
 Mar 20, 2019 HOLD Strong Buy
+662.6% avg upside
16 analysts
$9.00
597.76% Upside
 -32.2% ·
ANTH
Anthera Pharmaceuticals
 Dec 29, 2016 HOLD Buy
+472857042.9% avg upside
9 analysts
 — · ·
NTBLQ
Notable Labs
 Aug 13, 2015 HOLD Buy
+809999900.0% avg upside
12 analysts
 — · ·
VSTM
Verastem
 Apr 27, 2015 HOLD Strong Buy
+159.2% avg upside
24 analysts
 — · ·
ENLV
Enlivex
 Mar 31, 2015 BUY Strong Buy
+1842.0% avg upside
4 analysts
$32.00
1367.97% Upside
 · ·
OCUL
Ocular Therapeutix
 Mar 30, 2015 BUY Strong Buy
+189.9% avg upside
21 analysts
$49.00
476.47% Upside
 -78.0% ·
KPTI
Karyopharm Therapeutics
 Mar 16, 2015 BUY Strong Buy
+904.0% avg upside
18 analysts
$53.00
2674.83% Upside
 · ·
LSTA
Lisata Therapeutics
 Jan 09, 2015 BUY Buy
+1053.6% avg upside
11 analysts
$10.00
792.85% Upside
 · ·
SLS
SELLAS Life Sciences Group
 Nov 23, 2014 HOLD Strong Buy
+480.6% avg upside
16 analysts
 — · ·
IL:KMDA
Kamada
 Nov 21, 2014 HOLD Strong Buy
+77.2% avg upside
7 analysts
 — +28.2% ·
🔒 59 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Yigal Nochomovitz — Frequently Asked Questions
How accurate are Yigal Nochomovitz's stock ratings?
Based on the calls 13Foresight could measure, about 48% of Yigal's ratings were profitable over a one-year hold, with an average return of +4.8% per rating, or -1.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Yigal ranked on 13Foresight?
Yigal Nochomovitz is currently ranked #2463 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yigal cover?
Yigal most recently has ratings on ONC, SNDX, RARE, EYPT, TVTX, RIGL, KRYS, CRSP, SPTX, NBIX, SMMT, RCUS and 52 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.